{"id":"pazufloxacin","rwe":[{"pmid":"41468662","year":"2026","title":"Chiral separation of fluoroquinolones by capillary electrophoresis using glucosamine-functionalized carbon quantum dots as a Pseudostationary phase.","finding":"","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","studyType":"Clinical Study"},{"pmid":"41307508","year":"2025","title":"Chloride salts of the antibacterial agent pazufloxacin: (H(3)O)(2)(Pzfx)(5)Cl(7)·10H(2)O and (Pzfx)Cl·1.75H(2)O·0.5C(2)H(5)OH.","finding":"","journal":"Acta crystallographica. Section C, Structural chemistry","studyType":"Clinical Study"},{"pmid":"41062283","year":"2025","title":"(1)H-NMR Spectroscopy Study of the Formation of Inclusion Complexes between Cucurbit[7]uril and Ciprofloxacin, Levofloxacin, and Lomefloxacin.","finding":"","journal":"Chemical & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"40285583","year":"2025","title":"Amorphous Engineering Driving d-Orbital High Spin Configuration for Almost 100% (1)O(2)-Mediated Fenton-Like Reactions.","finding":"","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","studyType":"Clinical Study"},{"pmid":"40255794","year":"2025","title":"A Case of Legionella pneumophila With Hearing Loss Improved by Antimicrobial Therapy.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"tags":[{"label":"pazufloxacin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01MA18","category":"atc"},{"label":"Active","category":"status"},{"label":"Sepsis due to Streptococcus pneumoniae","category":"indication"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antitubercular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Topoisomerase II Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["pazufloxacin mesilate","pazufloxacin mesylate","pazufloxacin"],"offLabel":[],"synonyms":["pazufloxacin mesilate","pazufloxacin mesylate","pazufloxacin"],"timeline":[],"approvals":[],"ecosystem":[{"indication":"Sepsis due to Streptococcus pneumoniae","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"pazufloxacin","explanation":"Imagine your body's cells are like factories that make copies of themselves. Bacteria have their own factories too, and pazufloxacin stops these factories from working by blocking the enzymes that help them make copies of their DNA. This prevents the bacteria from growing and multiplying, ultimately helping to clear the infection.","oneSentence":"Pazufloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription.","technicalDetail":"Pazufloxacin exerts its antibacterial effects by binding to and inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and transcription, respectively."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2070","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PAZUFLOXACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PAZUFLOXACIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:14:40.744286","biosimilars":[],"competitors":[{"drugName":"ofloxacin","drugSlug":"ofloxacin","fdaApproval":"1990-12-28","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ciprofloxacin","drugSlug":"ciprofloxacin","fdaApproval":"1987-10-22","patentExpiry":"Nov 27, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enoxacin","drugSlug":"enoxacin","fdaApproval":"1991-12-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"norfloxacin","drugSlug":"norfloxacin","fdaApproval":"1986-10-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lomefloxacin","drugSlug":"lomefloxacin","fdaApproval":"1992-02-21","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"sparfloxacin","drugSlug":"sparfloxacin","fdaApproval":"1996-12-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"grepafloxacin","drugSlug":"grepafloxacin","fdaApproval":"1997-11-06","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"levofloxacin","drugSlug":"levofloxacin","fdaApproval":"1996-12-20","genericCount":36,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trovafloxacin","drugSlug":"trovafloxacin","fdaApproval":"1997-12-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"moxifloxacin","drugSlug":"moxifloxacin","fdaApproval":"1999-12-10","patentExpiry":"May 29, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"gemifloxacin","drugSlug":"gemifloxacin","fdaApproval":"2003-04-04","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gatifloxacin","drugSlug":"gatifloxacin","fdaApproval":"2003-03-28","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"delafloxacin","drugSlug":"delafloxacin","fdaApproval":"2017-06-19","patentExpiry":"Sep 23, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"pazufloxacin","indications":{"approved":[{"name":"Sepsis due to Streptococcus pneumoniae","source":"DrugCentral","snomedId":448421008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ofloxacin","brandName":"ofloxacin","genericName":"ofloxacin","approvalYear":"1990","relationship":"same-class"},{"drugId":"ciprofloxacin","brandName":"ciprofloxacin","genericName":"ciprofloxacin","approvalYear":"1987","relationship":"same-class"},{"drugId":"enoxacin","brandName":"enoxacin","genericName":"enoxacin","approvalYear":"1991","relationship":"same-class"},{"drugId":"norfloxacin","brandName":"norfloxacin","genericName":"norfloxacin","approvalYear":"1986","relationship":"same-class"},{"drugId":"lomefloxacin","brandName":"lomefloxacin","genericName":"lomefloxacin","approvalYear":"1992","relationship":"same-class"},{"drugId":"sparfloxacin","brandName":"sparfloxacin","genericName":"sparfloxacin","approvalYear":"1996","relationship":"same-class"},{"drugId":"grepafloxacin","brandName":"grepafloxacin","genericName":"grepafloxacin","approvalYear":"1997","relationship":"same-class"},{"drugId":"levofloxacin","brandName":"levofloxacin","genericName":"levofloxacin","approvalYear":"1996","relationship":"same-class"},{"drugId":"trovafloxacin","brandName":"trovafloxacin","genericName":"trovafloxacin","approvalYear":"1997","relationship":"same-class"},{"drugId":"moxifloxacin","brandName":"moxifloxacin","genericName":"moxifloxacin","approvalYear":"1999","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03696342","phase":"PHASE3","title":"Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-10-01","conditions":["Conjunctivitis, Bacterial"],"enrollment":46,"completionDate":"2020-03-24"},{"nctId":"NCT02980523","phase":"PHASE2","title":"Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-03","conditions":["Bacterial Conjunctivitis"],"enrollment":150,"completionDate":"2017-05"},{"nctId":"NCT03675841","phase":"PHASE1","title":"Pazufloxacin Mesilate Ear Drops in Patients With Chronic Suppurative Otitis Media","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-07-29","conditions":["Chronic Suppurative Otitis Media"],"enrollment":33,"completionDate":"2019-06-28"},{"nctId":"NCT02592096","phase":"PHASE1","title":"Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2015-07","conditions":["Otitis Media"],"enrollment":32,"completionDate":"2016-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"4CZ1R38NDI","CHEBI":"CHEBI:31964","INN_ID":"7247","UMLSCUI":"C0175022","ChEMBL_ID":"CHEMBL240163","KEGG_DRUG":"D01153","DRUGBANK_ID":"DB11774","PUBCHEM_CID":"65957","IUPHAR_LIGAND_ID":"12410","SECONDARY_CAS_RN":"163680-77-1","MESH_SUPPLEMENTAL_RECORD_UI":"C078052"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.1 hours","clearance":"4.87 mL/min/kg","fractionUnbound":"0.79%","volumeOfDistribution":"0.68 L/kg"},"publicationCount":136,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01MA18","allCodes":["J01MA18"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 1","pmid":"41468662","title":"Chiral separation of fluoroquinolones by capillary electrophoresis using glucosamine-functionalized carbon quantum dots as a Pseudostationary phase.","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"date":"2025 Dec 1","pmid":"41307508","title":"Chloride salts of the antibacterial agent pazufloxacin: (H(3)O)(2)(Pzfx)(5)Cl(7)·10H(2)O and (Pzfx)Cl·1.75H(2)O·0.5C(2)H(5)OH.","journal":"Acta crystallographica. Section C, Structural chemistry"},{"date":"2025","pmid":"41062283","title":"(1)H-NMR Spectroscopy Study of the Formation of Inclusion Complexes between Cucurbit[7]uril and Ciprofloxacin, Levofloxacin, and Lomefloxacin.","journal":"Chemical & pharmaceutical bulletin"},{"date":"2025 Jul","pmid":"40285583","title":"Amorphous Engineering Driving d-Orbital High Spin Configuration for Almost 100% (1)O(2)-Mediated Fenton-Like Reactions.","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"date":"2025 Mar","pmid":"40255794","title":"A Case of Legionella pneumophila With Hearing Loss Improved by Antimicrobial Therapy.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","brandName":"PAZUFLOXACIN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pazufloxacin is a small molecule antibiotic belonging to the fluoroquinolone class. It is used to treat sepsis caused by Streptococcus pneumoniae. The commercial status of pazufloxacin is unclear, but it is likely patented. Key safety considerations include its potential to cause tendon damage and central nervous system effects. Further research is needed to fully understand its pharmacokinetics and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}